140 related articles for article (PubMed ID: 25970717)
41. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
Lax SF
Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
[TBL] [Abstract][Full Text] [Related]
42. New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
Gadducci A; Guerrieri ME; Genazzani AR
Gynecol Endocrinol; 2012 Aug; 28(8):582-6. PubMed ID: 22304686
[TBL] [Abstract][Full Text] [Related]
43. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
[TBL] [Abstract][Full Text] [Related]
44. Dedifferentiated carcinoma with clear cell carcinoma of the endometrium: A case report.
Lee SE; Park HY; Shim SH; Kim WY
Pathol Int; 2017 Sep; 67(9):472-476. PubMed ID: 28667682
[TBL] [Abstract][Full Text] [Related]
45. Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.
Depreeuw J; Hermans E; Schrauwen S; Annibali D; Coenegrachts L; Thomas D; Luyckx M; Gutierrez-Roelens I; Debruyne D; Konings K; Moerman P; Vergote I; Lambrechts D; Amant F
Gynecol Oncol; 2015 Oct; 139(1):118-26. PubMed ID: 26232337
[TBL] [Abstract][Full Text] [Related]
46. A multiomics comparison between endometrial cancer and serous ovarian cancer.
Zhong H; Chen H; Qiu H; Huang C; Wu Z
PeerJ; 2020; 8():e8347. PubMed ID: 31942259
[TBL] [Abstract][Full Text] [Related]
47. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
48. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
49. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
[TBL] [Abstract][Full Text] [Related]
50. The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility.
Hussein YR; Broaddus R; Weigelt B; Levine DA; Soslow RA
Int J Gynecol Pathol; 2016 Jan; 35(1):16-24. PubMed ID: 26166718
[TBL] [Abstract][Full Text] [Related]
51. Molecular characterization of endometrial cancer and therapeutic implications.
Uppendahl L; Mullany SA; Winterhoff B
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):35-39. PubMed ID: 27941362
[TBL] [Abstract][Full Text] [Related]
52. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium.
Iwamoto M; Nakatani Y; Fugo K; Kishimoto T; Kiyokawa T
Hum Pathol; 2015 Jul; 46(7):957-62. PubMed ID: 25971546
[TBL] [Abstract][Full Text] [Related]
53. Classification of endometrial carcinoma: more than two types.
Murali R; Soslow RA; Weigelt B
Lancet Oncol; 2014 Jun; 15(7):e268-78. PubMed ID: 24872110
[TBL] [Abstract][Full Text] [Related]
54. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
Bartosch C; Manuel Lopes J; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
[TBL] [Abstract][Full Text] [Related]
55. Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumor.
Schrauwen S; Coenegrachts L; Depreeuw J; Luyten C; Verbist G; Debruyne D; Vergote I; Lambrechts D; Amant F
Int J Gynecol Cancer; 2015 Mar; 25(3):363-71. PubMed ID: 25695543
[TBL] [Abstract][Full Text] [Related]
56. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
57. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
58. Molecular insights into the classification of high-grade endometrial carcinoma.
Hussein YR; Soslow RA
Pathology; 2018 Feb; 50(2):151-161. PubMed ID: 29246451
[TBL] [Abstract][Full Text] [Related]
59. Precursors and pathogenesis of ovarian carcinoma.
Lim D; Oliva E
Pathology; 2013 Apr; 45(3):229-42. PubMed ID: 23478230
[TBL] [Abstract][Full Text] [Related]
60. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
García-Sanz P; Triviño JC; Mota A; Pérez López M; Colás E; Rojo-Sebastián A; García Á; Gatius S; Ruiz M; Prat J; López-López R; Abal M; Gil-Moreno A; Reventós J; Matias-Guiu X; Moreno-Bueno G
Int J Cancer; 2017 Apr; 140(7):1551-1563. PubMed ID: 27997699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
